- Home
- PEW vs ADAG Comparison
PEW vs ADAG Comparison
Compare PEW & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.17
HOLD
Current Price
$1.77
Company Overview
Basic Information| Metric | PEW | ADAG |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PEW | ADAG |
|---|---|---|
| Price | $3.17 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 527.8K | 44.4K |
| Earning Date | 02-14-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $92,782,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $6.69 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $1.30 |
| 52 Week High | $21.40 | $3.16 |
Technical Indicators
Market Signals| Indicator | PEW | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 47.90 |
| Support Level | $3.00 | $1.75 |
| Resistance Level | $3.26 | $1.83 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 58.33 | 42.86 |
Price Performance
Historical Comparison PEW
ADAG
About PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.